Profile data is unavailable for this security.
About the company
Orion Oyj is a Finland-based company engaged in the development, manufacture and marketing of pharmaceuticals and diagnostic tests. The Company operates, along with its subsidiaries, in two business segments: the Pharmaceuticals business segment develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients, and the Diagnostics business segment develops, manufactures and markets diagnostic tests. The Company’s business comprises two main divisions: Proprietary Products and Specialty Products. Its Proprietary Products consist of patented prescription products in three therapy areas: central nervous system diseases, oncology and critical care, and Easyhaler pulmonary drugs. The Company’s Specialty Products, which include the provision of generic prescription drugs and self-care products for basic healthcare. In addition the Company also produces veterinary medicines for pets and production animals.
- Revenue in EUR (TTM)1.89bn
- Net income in EUR500.40m
- Incorporated2006
- Employees4.03k
- LocationOrion OyjOrionintie 1AESPOO 02200FinlandFIN
- Phone+358 104261
- Fax+358 104264435
- Websitehttps://www.orionpharma.com/
| Holder | Shares | % Held |
|---|---|---|
| Keskin�inen El�kevakuutusyhti� Ilmarinenas of 30 Sep 2025 | 1.83m | 5.78% |
| Keskin�inen Ty�el�kevakuutusyhti� Eloas of 30 Sep 2025 | 291.80k | 0.92% |
| Guardians of New Zealand Superannuationas of 30 Jun 2025 | 255.98k | 0.81% |
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 159.63k | 0.51% |
| Jenny ja Antti Wihurin rahasto sras of 30 Sep 2025 | 123.84k | 0.39% |
| Handelsbanken Fonder ABas of 31 Jan 2026 | 119.31k | 0.38% |
| abrdn Investment Management Ltd.as of 31 Jul 2024 | 44.66k | 0.14% |
| Nordea Investment Management AB (Denmark)as of 30 Sep 2025 | 43.81k | 0.14% |
| BlackRock Advisors (UK) Ltd.as of 31 Oct 2025 | 38.50k | 0.12% |
| Robeco Institutional Asset Management BVas of 30 Sep 2025 | 32.06k | 0.10% |
